Learning Center

Learning Center

December 2022 - Quality Bone Densitometry: Performance, Interpretation, and Clinical Application for Clinicians

  • Register
    • Non-Member - $575
    • Full Member - $375
    • MOC Only - $575
    • Community Member - $575
    • Professional Member - $575

This activity will be offered through zoom, allowing the learner to watch and ask questions in a live format on December 10 & 11, 2022. Learners will be asked to complete a post-course survey to indicate what they will change in their practice as a result of this activity. An Osteoporosis Essentials Course of the International Society for Clinical Densitometry & International Osteoporosis Foundation

The core elements of this course serve to educate healthcare providers about bone densitometry and osteoporosis and to apply standard practices to assure quality performance and interpretation of bone densitometry studies. The course is offered in two parts. The first day sets the standard to perform Quality DXA interpretation. Day 2 focuses on the clinical assessment, prevention, treatment and management of osteoporosis and the essential role that high-quality DXA plays in treatment initiation decisions and monitoring of osteoporotic patients. Individuals may register for either part of the course separately or as a combined program.

Prerequisite videos are included in the registration fees. Access to that content will be made available to registrants through the ISCD online education website 30 days prior to the course. 

Registration Fees


Target Audience

The course is most appropriate for those involved in the performance and interpretation of DXA scans and those managing patients with osteoporosis. It is open to MDs, PhDs, DOs, Nurse Practitioners, and Physician Assistants. Technologists may attend if they have previously taken the ISCD/IOF Osteoporosis Essentials for Technologists Course.

Overall Course Objectives

After attending the course, participants should be better prepared to:

  • Describe appropriate clinical evaluation of patients at risk for fragility fracture.
  • Summarize the value and importance of quality bone densitometry for the diagnosis of osteoporosis, assessment of fracture risk, and monitoring of BMD. 
  • Recognize errors in DXA analysis and reporting. 
  • Explain new and emerging guidelines that provide evidence-based information regarding skeletal health. 
  • Describe the use of current and new pharmacologic therapies for the management and treatment of osteoporosis, including adverse effects.

Method of Participation

This activity will be offered through zoom, allowing the learner to watch and ask questions in a live format on December 10 & 11, 2022. Learners will be asked to complete a post-course survey to indicate what they will change in their practice as a result of this activity.

Accreditation Statement

The International Society for Clinical Densitometry is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity is provided by the International Society for Clinical Densitometry and has been designated for up to 11.5 AMA PRA Category 1 Credits TM. For information about the accreditation of this program, please contact ISCD at +1.860.259.1000 or inquire at education@iscd.org.

Instructions to Receive Credit

Physicians will be required to complete an evaluation of the activity online after the conclusion of the activity. As a part of that evaluation, they will claim the amount of credit commensurate with the extent of their participation in the activity. After completing the evaluation, a certificate will be generated that the physician may print to indicate credits earned.

 Schedule - All times eastern (NYC/USA)

 Schedule - All times eastern (NYC/USA)



The International Society for Clinical Densitometry designates this live educational activity for a maximum of  11.50 AMA PRA Category 1 Credits™. Physicians should only claim credits commensurate with the extent of their participation in the activity

Steven M. Petak, MD, JD, MACE, FACP

Division Head and Clinical Service Chief Endocrinology

Houston Methodist Hospital

Dr. Steven Petak is a clinical and academic endocrinologist in Houston, Texas.

He is a past president of the American Association of Clinical Endocrinologists, the American College of Endocrinology (www.aace.com), and the International Society for Clinical Densitometry (www.iscd.org). He is an associate clinical professor at Weill-Cornell Medical College at the Houston Methodist Hospital and is the division head of endocrinology, diabetes and metabolism as well as service chief of endocrinology. He is a bone densitometry and endocrine consultant to NASA at the Johnson Space Center for about 13 years and has been a part of the bone summit planning long duration space missions. He is the secretary of the board of councilors of the Texas Medical Association (2015) and represents the Harris County Medical Society as vice-councilor.

His awards include Master of the American College of Endocrinology, Yank Coble Public Service Award of the American College of Endocrinology, the ISCD Paul Miller Public Service Award, and ISCD Clinician of the Year. He has authored and co-authored articles, editorials and guidelines in endocrinology and reproductive medicine.

He received his MD from the University of Illinois in Chicago and has his JD from the University of Houston (Magna cum Laude). He had his internship, residency, medical chief residency, and fellowship in endocrinology and metabolism at the University of Texas at Houston. He was at the Texas Institute for Reproductive Medicine and Endocrinology in Houston for about 26 years before joining the academic endocrine group at Methodist in May 2013. He is board certified in internal medicine as well as endocrinology and metabolism.

Disclosures: Fees for Non-CME Services: Amgen, Alexion, Shire, Alexion 

S. Bobo Tanner, MD, CCD

Director of the Vanderbilt Osteoporosis Clinic

Vanderbilt University Medical Center

Bobo Tanner, MD, CCD is an Assistant Professor of Medicine at Vanderbilt University Medical Center in Nashville, TN in the Divisions of Rheumatology, Allergy and Immunology. He is the
Director of the Vanderbilt Osteoporosis Clinic. His education includes an AB from Harvard University, and an MD from Wake Forest University. He completed his training in Internal
Medicine, Rheumatology, and Allergy & Immunology at Vanderbilt University and served as Registrar in Rheumatology at the Royal Free Hospital, London, England. Dr. Tanner has been a
member of the International Society for Clinical Densitometry (ISCD) since 1996 and is a Past- President of the ISCD. He is an Osteoporosis Essentials Course instructor, serves on the OE Update
Committee and CME Committee. He was awarded Clinical Densitometrist of the year in 2007 by the ISCD and was Co-Chair of the ISCD Annual Meeting in 2006. He is a reviewer for the Journal of
Clinical Densitometry and is on the editorial board of Therapeutic Advances in Musculoskeletal disease. He has also participated in numerous advisory boards and has given a variety of CME
presentations. His research has been presented in regional, national, and international academic meetings.

Disclosures: Consulting Fees: AMGA, CSL Behring, Radius, Ultragenyx; Fees for Non-CME Services: Regeneron, Sanofi/GENZYME; Contracted Research: Amgen

Neil Binkley, MD, CCD

Professor of Medicine

University of Wisconsin-Madison

Dr. Neil Binkley earned his medical degree from the University of Wisconsin and subsequently trained in Internal Medicine at the Marshfield Clinic. After several years in private practice, he returned to the University of Wisconsin and completed a Geriatrics fellowship. He is a Professor in the Divisions of Geriatrics and Endocrinology at the University of Wisconsin School of Medicine and Public Health. He is also Director of the UW Osteoporosis Clinical Research Program and Associate Director of the UW Institute on Aging. He is past President of the International Society for Clinical Densitometry, Associate Editor of Osteoporosis International and a member of the International Osteoporosis Foundation Committee of Scientific Advisors. His current research involves improvement in 25(OH)D measurement, evaluation of approaches to optimize assessment of vitamin D status, evaluation of functional assessment in older adults and the importance of sarcopenia in fracture risk. Dr. Binkley has published over 300 papers, served on expert committees and panels for AACE, ASBMR, IOF and ISCD.

Disclosures: Amgen (Self) : Consultant (Status: Ongoing); Radius (Self) : Research Support (Status: Ongoing)

Statement of independence
The ISCD maintains a policy on the use of commercial support, which ensures that all educational activities sponsored by the ISCD provide in-depth presentations that are fair, balanced, independent, and scientifically rigorous. ISCD requires faculty, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ISCD for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Individual disclosures are included in course material. No Commercial Support has been provided for this activity

The information and suggestions presented at the courses, seminars and other programs sponsored by ISCD and other collaborating societies are subject to change and therefore should serve only as a foundation for further investigation and study. Any forms presented at our seminars or programs are samples only and are not necessarily authoritative. All information, procedures, and forms contained or used in such seminars or programs should serve only as a guide for use in specific situations.

Disclosure of Unlabeled Use 
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. ISCD does not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Privacy & Confidentiality Statement
The ISCD will record learner’s personal information as provided on evaluations to allow for issuance and tracking of CME/CE certificates. The ISCD may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its educational program. No individual performance data or any other personal information collected for evaluations will be shared with third parties

Attendance Cancellation Policy
All changes in registration must be made in writing to education@iscd.org. Cancellations received 30 days prior to the start of the program are eligible for a full refund minus a $50 administrative fee. Cancellations received less than 30 days prior to the start of the course will not be refunded.

Course Changes or Cancellations
ISCD reserves the right to cancel the program, change dates and/or meeting location. If a program is canceled, all program fees will be refunded automatically unless the registered participant elects to transfer to another program. Participants will be notified of any changes within 21 days of the course start date.

This content will not be available until 11/12/2022 at 11:36 AM (EST)